FOLLI, FRANCO
FOLLI, FRANCO
Dipartimento di Scienze della Salute
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
2026 M. Colognesi, D. Gabbia, A. Signor, M. Sarill, L. Centofanti, A. Rinaldi, L. Cascione, S. Nunziata, M. Banzato, A. Mattarei, G. Finzi, S. Sonda, D. Pendin, I. Zanotto, S. Comai, G. Pasut, A. Alajati, M. Saponaro, L. Bucciarelli, M.E. Lunati, G. Guarato, I. Goggi, S. La Rosa, C. Morano, R.C. Paroni, M.V. Dei Cas, G. Daniele, M. Gentilucci, M. Pappagallo, A. Alimonti, P.L. Manfredi, F. Folli, S. De Martin
The interaction between glucose levels and body mass index on the regulation of the circulating sphingolipidome in humans
2026 C. Morano, L. Centofanti, M. Dei Cas, R. Zanzi, G. De Pinto, M. Bignotto, P. Zermiani, E. Bianco, F. Samartin, S. Penati, I. Pes, I. Goggi, P. Senesi, G. Serrao, L. Bucciarelli, F. Bravi, A. Russo, M. Trinchera, P. Battezzati, M. Ferraroni, F. Folli, R. Paroni
TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis
2025 F. D'Addio, G. Amabile, E. Assi, A. Maestroni, A. Petrazzuolo, C. Loretelli, A. Abdelasalam, M. Ben Nasr, I. Pastore, M.E. Lunati, V. Usuelli, M. Zocchi, A.J. Seelam, D. Corradi, S. La Rosa, V. Marin, M. Zangarini, M. Nardini, S. Porzio, F. Canducci, C. Nardini, B. El Essawy, M. Nebuloni, J. Yang, M. Venturini, G. Maconi, F. Folli, S. Danese, G. Zuccotti, G.M. Sampietro, S. Ardizzone, P. Fiorina
Lipidome profile of Cystic Fibrosis Related Diabetes, Type 1 and Type 2 Diabetes Mellitus: potential links to inflammation and glucose and lipid metabolism
2025 A. Mingione, C. Loretelli, M. Dei Cas, F. Pivari, M. Barcella, I. Merelli, A. Zulueta, R. Paroni, L.C. Morlacchi, V. Vaira, F. Gillani, M. Piccoli, L. Anastasia, E. Albi, I. Righi, M. Nosotti, P. Fiorina, A. Caretti, L. Rosso, F. Folli, P. Signorelli
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis
2025 C. Guidetti, G.I. Papakostas, L. Pani, S.D. Martin, G. Serra, M. Apicella, C. Kröger, P. Champasa, S. Comai, A. Mattarei, F. Folli, M. Pappagallo, P.L. Manfredi, M. Fava
Analysis of morbid obese diabetic and non-diabetic patients: clinical and social characteristics, habits and workup to undergo bariatric surgery in Lombardy, Italy
2025 A.E. Pontiroli, S. Guarino, M. Tagliabue, L. La Sala, L. Centofanti, S. Olmi, G. Sarro, A. Giovanelli, C. Asteria, E. Galfrascoli, U. Mortola, L. Bucciarelli, M.A. Zappa, E. Tagliabue, F. Folli
Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study
2025 C. Berra, R. Manfrini, F. Bifari, E. Cipponeri, R. Ghelardi, L. Centofanti, U. Mortola, E. Lunati, L. Bucciarelli, V. Cimino, F. Folli
Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements
2025 D. Chiumello, M. Passeri, S. Coppola, E. Chiodaroli, S. Carnier, M. Montante, T. Pozzi, I. Goggi, F. Bifari, U. Mortola, L. Centofanti, F. Folli
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder
2025 M. Fava, L. Pani, S.D. Martin, A.J. Cutler, C.W. Gorodetzky, F.J. Vocci, F.L. Sapienza, T.R. Kosten, C. Kröger, P. Champasa, C. Guidetti, S. Comai, A. Mattarei, F. Folli, D. Bushnell, S. Traversa, C.E. Inturrisi, P.L. Manfredi, M. Pappagallo
Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis
2024 A. Galli, S. Moretti, N. Dule, E.S. Di Cairano, M. Castagna, P. Marciani, C. Battaglia, F. Bertuzzi, I. Pastore, P. Fiorina, S. La Rosa, A. Davalli, F. Folli, C. Perego
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)
2024 C. Guidetti, S.D. Martin, G. Serra, M. Apicella, L. Pani, M. Pappagallo, A. Mattarei, F. Folli, P. Manfredi, M. Fava
The triglyceride-glucose index, blood glucose levels, and metabolic syndrome are associated with all-cause mortality in obesity
2024 A.E. Pontiroli, L. Centofanti, A.S. Zakaria, S. Cerutti, M. Dei Cas, R. Paroni, L. La Sala, E. Tagliabue, S. Magnani, F. Folli
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
2024 M. Ben Nasr, V. Usuelli, S. Dellepiane, A.J. Seelam, T.V. Fiorentino, F. D'Addio, E. Fiorina, C. Xu, Y. Xie, H.B. Balasubramanian, E. Castillo-Leon, L. Loreggian, A. Maestroni, E. Assi, C. Loretelli, A. Abdelsalam, B. El Essawy, S. Uccella, I. Pastore, M.E. Lunati, G. Sabiu, A. Petrazzuolo, G. Ducci, E. Sacco, L. Centofanti, M. Venturini, S. Mazzucchelli, D. Mattinzoli, M. Ikehata, G. Castellano, G. Visner, L. Kaifeng, K.M. Lee, Z. Wang, D. Corradi, S. La Rosa, S. Danese, J. Yang, J.F. Markmann, G.V. Zuccotti, R. Abdi, F. Folli, P. Fiorina
Investigating the Impact of Epstein-Barr Virus on Sphingolipid Composition in Extracellular Vesicles of Multiple Sclerosis Patients
2024 L. Centofanti, A. Zollo, M. Dei Cas, V. Citro, D. Giannandrea, E. Soleymaninejadian, A. Mingione, A. Corona, A. Priori, M. Miozzo, F. Folli, R. Paroni, R. Chiaramonte, F. Martinelli Boneschi
N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity
2024 S. Comai, S. De Martin, A. Mattarei, C. Guidetti, M. Pappagallo, F. Folli, A. Alimonti, P.L. Manfredi
The Relationship of Glucose Intolerance/Diabetes and Overweight/Obesity with Sphingolipidoma Alterations
2024 C. Morano, L. Centofanti, M.V. DEI CAS, S. Penati, E. Bianco, M. Bignotto, C. Berra, P. Zermiani, R. Paroni, P.M. Battezzati, F. Folli
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
2024 M. Fava, S.M. Stahl, L. Pani, S.D. Martin, A.J. Cutler, V. Maletic, C.W. Gorodetzky, F.J. Vocci, F.L. Sapienza, T.R. Kosten, C. Kröger, P. Champasa, C. O'Gorman, C. Guidetti, A. Alimonti, S. Comai, A. Mattarei, F. Folli, D. Bushnell, S. Traversa, C.E. Inturrisi, P.L. Manfredi, M. Pappagallo
Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study
2024 C. Berra, R. Manfrini, F. Bifari, E. Cipponeri, R. Ghelardi, L. Centofanti, U. Mortola, E. Lunati, L. Bucciarelli, V. Cimino, F. Folli
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
2024 N. Ferri, S. De Martin, J. Stuart, S. Traversa, A. Mattarei, S. Comai, F. Folli, M. Pappagallo, C. Guidetti, C.E. Inturrisi, P.L. Manfredi
Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population. CA.ME.LI.A study 7 year follow-up
2024 M. Bignotto, E. Bianco, L. Centofanti, A. Russo, M. Dei Cas, P. Zermiani, C. Morano, F. Samartin, E. Bertolini, F. Bifari, C. Berra, M. Zuin, R. Paroni, P.M. Battezzati, F. Folli